Patents by Inventor Chien-Tsun Kuan
Chien-Tsun Kuan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160272730Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: ApplicationFiled: June 2, 2016Publication date: September 22, 2016Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTHInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Patent number: 9441048Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: GrantFiled: November 15, 2011Date of Patent: September 13, 2016Assignees: The United States of America as represented by the Secretary of Health and Human Services, Duke UniversityInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Publication number: 20160168263Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.Type: ApplicationFiled: July 9, 2014Publication date: June 16, 2016Applicants: DUKE UNIVERSITY, THE GOVERNMENT OF THE U.S. AS REPRESENTED BY THE SECRETARY OF HEALTHInventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
-
Patent number: 9353418Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: December 11, 2013Date of Patent: May 31, 2016Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Patent number: 9249217Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.Type: GrantFiled: November 15, 2011Date of Patent: February 2, 2016Assignees: Secretary, DHHS, Duke UniversityInventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
-
Publication number: 20150368353Abstract: Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified Pseudomonas exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.Type: ApplicationFiled: June 1, 2015Publication date: December 24, 2015Inventors: Darell BIGNER, Chien-Tsun KUAN, Ira H. PASTAN, Vidyalakshmi CHANDRAMOHAN
-
Patent number: 9115196Abstract: The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiforme cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. The antibodies may be formed in cells transformed with an isolated nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region (“VH”) and an antibody light chain variable region (“VL”). Such nucleic acids are provided.Type: GrantFiled: May 20, 2013Date of Patent: August 25, 2015Inventors: Chien-Tsun Kuan, Darell D. Bigner, Ira H. Pastan
-
Publication number: 20150132306Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents.Type: ApplicationFiled: June 7, 2013Publication date: May 14, 2015Inventors: Darell Bigner, Chien-Tsun Kuan, John Sampson, Bryan Choi, Ira H. Pastan
-
Publication number: 20140322248Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: May 6, 2014Publication date: October 30, 2014Inventors: Darell BIGNER, Chien-Tsun KUAN, Ira H. PASTAN, Charles PEAGRAM
-
Patent number: 8835608Abstract: An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells expression the MRP3 antigen, as well as kits, nucleic acids, polypeptides, and cells for providing the antibodies.Type: GrantFiled: November 30, 2007Date of Patent: September 16, 2014Assignee: Duke UniversityInventors: Chien-Tsun Kuan, Darell D Bigner
-
Publication number: 20140187764Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: December 11, 2013Publication date: July 3, 2014Applicants: Duke University, The Johns Hopkins UniversityInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Patent number: 8685660Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: GrantFiled: September 3, 2009Date of Patent: April 1, 2014Assignees: The Johns Hopkins University, Duke UniversityInventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
-
Publication number: 20140017266Abstract: Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified Pseudomonas exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.Type: ApplicationFiled: December 5, 2011Publication date: January 16, 2014Applicants: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HHS, NIH, DUKE UNIVERSITYInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Vidyalakshmi Chandramohan
-
Publication number: 20140010829Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: ApplicationFiled: November 15, 2011Publication date: January 9, 2014Applicants: The Gov't of the United States, as Represented by, The Secretary of Health and Human Services, DUKE UNIVERSITYInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Publication number: 20130245244Abstract: The invention provides high affinity antibodies suitable for forming immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiforme cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells. The antibodies may be formed in cells transformed with an isolated nucleic acid encoding a polypeptide comprising an antibody heavy chain variable region (“VH”) and an antibody light chain variable region (“VL”). Such nucleic acids are provided.Type: ApplicationFiled: May 20, 2013Publication date: September 19, 2013Applicants: DUKE UNIVERSITY, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALInventors: Chien-Tsun KUAN, Darell D. BIGNER, Ira H. PASTAN
-
Patent number: 8445216Abstract: The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.Type: GrantFiled: October 18, 2011Date of Patent: May 21, 2013Assignees: Duke University, The United States of America, as represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Chien-Tsun Kuan, Darell D Bigner, Ira H Pastan
-
Publication number: 20130022598Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: May 29, 2012Publication date: January 24, 2013Applicants: The United States Government as represented by the Secretary, Department of Health and Human Service, Duke UniversityInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles N. Pegram
-
Publication number: 20120202207Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.Type: ApplicationFiled: March 6, 2012Publication date: August 9, 2012Applicants: DUKE UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, D. Williams PARSONS, Xiaosong ZHANG, Jimmy Cheng-Ho LIN, Rebecca J. LEARY, Philipp ANGENENDT, Nickolas PAPADOPOULOS, Victor VELCULESCU, Giovanni PARMIGIANI, Rachel KARCHIN, Sian JONES, Hai YAN, Darell BIGNER, Chien-Tsun KUAN, Gregory J. RIGGINS
-
Publication number: 20120189630Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents.Type: ApplicationFiled: November 15, 2011Publication date: July 26, 2012Applicant: DUKE UNIVERSITYInventors: Darell D. BIGNER, Chien-Tsun KUAN, John H. SAMPSON, Mingqing CAI, Bryan D. CHOI
-
Publication number: 20120122121Abstract: The invention provides high affinity antibodies suitable for forming Immunotoxins that inhibit the growth of cells expressing human glycoprotein NMB, including glioblastoma multiform cells, anaplastic astrocytoma cells, anaplastic oligodendroglioma cells, oligodendroglioma cells, and melanoma cells.Type: ApplicationFiled: October 18, 2011Publication date: May 17, 2012Applicants: Duke University, The Government of The United States as Represented by The Secretary of HealthInventors: Chien-Tsun KUAN, Darell D. BIGNER, Ira H. PASTAN